In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicity

Tumor Biology

Volumn 29, Issue 6, 2008, Pages 359-370

  Li, Xiao Lin ^a   Zhang, Dong Qing ^d   Wang, David ^a   Knight, David S ^a   Yin, Lija ^a   Bao, Jianxiong ^b   Liu, Yong Yu ^c   Glass, Jonathan ^a   Mathis, J Michael ^a   Zhang, Qian Jin ^a,e  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

^c UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e Health Science Center   (United States)

Author keywords

Genetic alterations; Immune response; Ovarian epithelial cancer; Tumorigenicity

Indexed keywords

COLLAGEN; COLLAGEN TYPE 4 ALPHA5; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENE PRODUCT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; MESSENGER RNA; RANTES; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CARCINOGENICITY; CELL CLONE; CELL SURVIVAL; CELL TRANSFORMATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH RATE; IMMUNOCOMPETENCE; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVARY CELL; PERITONEAL CAVITY; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSLATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

EID: 57049141520     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178981     Document Type: Article

References (30)

1. Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC: Models of ovarian cancer: are we there yet? Mol Cell Endocrinol 2005;239:15-26.
2. Wilson AP: Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst 1984;72:513-521.
3. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF: Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-591.
4. Urzua U, Frankenberger C, Gangi L, Mayer S, Burkett S, Munroe DJ: Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. Tumour Biol 2005;26:236-244.
5. Urzua U, Roby KF, Gangi LM, Cherry JM, Powell JI, Munroe DJ: Transcriptomic analysis of an in vitro murine model of ovarian carcinoma: functional similarity to the human disease and identification of prospective tumoral markers and targets. J Cell Physiol 2006;206:594-602.
6. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC: Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992;84:592-601.
7. Ge HL, Zhang XR, Wang Y, Ma AL, Zhang HZ, Wang SJ, Zhou GY: Study of HLA molecules and its associated genes expression in human ovarian cancer cells (in Chinese). Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003;19:41-44.
8. Seliger B, Maeurer MJ, Ferrone S: TAP off - tumors on. Immunol Today 1997;18:292-299.
9. Zhang QJ, Li XL, Wang D, Huang XC, Mathis JM, Duan WM, Knight D, Shi R, Glass J, Zhang DQ, Eisenbach L, Jefferies WA: Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses. PLoS ONE 2008;3:e3097.
10. Woods LK, Morgan RT, Quinn LA, Moore GE, Semple TU, Stedman KE: Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res 1979;39:4449-4459.
11. DiSaia PJ, Morrow M, Kanabus J, Piechal W, Townsend DE: Two new tissue culture lines from ovarian cancer. Gynecol Oncol 1975;3:215-219.
12. Shin SI, Freedman VH, Risser R, Pollack R: Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 1975;72:4435-4439.
13. Colburn NH, Bruegge WF, Bates JR, Gray RH, Rossen JD, Kelsey WH, Shimada T: Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res 1978;38:624-634.
14. Pardoll D: Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-839.
15. Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC: Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007;67:1832-1841.
16. Zhang QJ, Seipp RP, Chen SS, Vitalis TZ, Li XL, Choi KB, Jeffries A, Jefferies WA: TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma. Int J Cancer 2007;120:1935-1941.
17. Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ: Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 2001;207:81-88.
18. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-378.
19. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-289.
20. Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I, Schroder JM, Schadendorf D: The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999;79:1025-1031.
21. Vicari AP, Caux C: Chemokines in cancer. Cytokine Growth Factor Rev 2002;13:143-154.
22. Kundu N, Dorsey R, Jackson MJ, Guiterrez P, Wilson K, Fu S, Ramanujam K, Thomas E, Fulton AM: Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer 1998;76:713-719.
23. Neville LF, Mathiak G, Bagasra O: The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997;8:207-219.
24. Lazzeri E, Romagnani P: CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:109-118.
25. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981-992.
26. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67:3396-3405.
27. Kollmar O, Junker B, Rupertus K, Menger MD, Schilling MK: Studies on MIP-2 and CXCR2 expression in a mouse model of extrahepatic colorectal metastasis. Eur J Surg Oncol 2007;33:803-811.
28. Faunce DE, Sonoda KH, Stein-Streilein J: MIP-2 recruits NKT cells to the spleen during tolerance induction. J Immunol 2001;166:313-321.
29. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H: The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
30. Dvorkin T, Song X, Argov S, White RM, Zoller M, Segal S, Dinarello CA, Voronov E, Apte RN: Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha. J Leukoc Biol 2006;80:96-106.